DOCSLIB.ORG

Cutaneous Necrosis Due to Norepinephrine: * II

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cutaneous Necrosis Due to Norepinephrine: * II Cutaneous Necrosis Due to Norepinephrine: * II. Mechanism and Prevention A. STEPHEN CLOSE, M.D., WILLIAM H. FRACKELTON, M.D., Ross C. KORY, M.D. From the Department of Surgery, Wood Veterans Administration Hospital and Marquette University School of Medicine, Milwaukee, Wisconsin THE increased use of norepinephrine systemically administered epinephrine or (Levophed®) during recent years has been norepinephrine. , 2,12,16,18 Chambers and accompanied by more frequent reports of Zweifach 6 have shown that this constrictor cutaneous necrosis resulting from its ad- response is accentuated during hypotension ministration by continuous intravenous in- produced by hemorrhage or trauma, an im- fusion. Although these complications have portant observation, since hypotension is not resulted in serious threat to life, the almost invariably present in the clinical prolongation of hospitalization and eco- situations in which norepinephrine is used. nomic loss may be of considerable mag- These facts explain how slough results nitude by the time a large slough of skin when a solution of norepinephrine extra- of an extremity has been removed and the vasates and infiltrates the subcutaneous defect grafted and healed. In a recent re- layer. They do not explain how a slough port7 61 documented instances of cutane- results when the vein is securely tied ous necrosis occurring in 50 patients during around a plastic catheter. Two main the- the period between January 1951 and April ories have been advanced to explain such 1956 were collected. a slough. One theory suggests that spasm The present study is concerned with two in the "infusion" vein leads to backflow separate aspects of this problem: a) The through its tributaries and results in pro- mechanisms involved in the production of longed venular and arteriolar spasm,3 17 cutaneous necrosis by norepinephrine, and and that the reduced venous pressure as- b) The efficacy of two adrenergic blocking sociated with arterial hypotension may pro- agents in the prevention of such necrosis. mote backflow due to the hydrostatic pres- sure of the infusion. The second theory I. Mechanism of Slough maintains that spasm of the "infusion" vein and its vasa vasorum leads to diffusion of The ultimate cause of skin necrosis dur- norepinephrine through the vein wall.8 15 ing norepinephrine infusion is considered The relationship of the area of necrosis to to be intense and prolonged ischemia of the the tip of the catheter and the course of the skin and subcutaneous tissues due to marked vein favors the latter theory. Only one au- constriction of the vessels supplying these thor 19 has allocated any causal importance tissues. Constriction has been shown to be to thrombosis of the infusion vein. Many the uniform response of these vessels to have agreed that inadequate flow through the distally ligated infusion vein is prob- * Submitted for publication April 22, 1957. This investigation was supported in part by a ably of some importance since it prevents Research Grant from CIBA Pharmaceutical Prod- sufficient dilution of the drug within the ucts, Inc. vein. 44 Volume 147 CUTANEOUS NECROSIS DUE TO Number 1 NOREPINEPHRINE 45 Experimental Results jacent to the infusion vein. This blanching paralleled the infusion vein, rather than the In five dogs the lesser saphenous vein tributary veins. A large necrotic area de- was exposed for about four to five inches veloped along the skin incision in one of by gentle dissection. A polyethylene cath- these dogs. eter was inserted one inch into the vein and Thrombosis occurred in two of the seven the vein securely tied around the catheter infusions veins but involved only the seg- to it. In no instance this re- and distal did ment between the vein ligature and the sult in significant spasm of the vein. A mix- catheter tip. ture of four mg. of norepinephrine in one liter of five per cent dextrose solution was allowed to drip slowly (12 to 18 drops per II. Prevention of Slough minute) into the vein. In four of the five The measures commonly recommended dogs intense spasm at the level of the for the prevention of slough have included catheter tip developed in ten to 100 sec- administration of norepinephrine in the onds. During the next few minutes spasm muscular part of the arm, use of a catheter gradually extended up the entire visible rather than a needle, and passage of long length of the vein. At the same time the plastic catheters into major veins in the tributary veins became spastic at their junc- thoracic or abdominal cavities to provide tions with the infusion vein. The skin inci- greater dilution of the drug by the in- sion was then closed with clips and opened creased blood flow. for inspection of the vein every half hour. Hot packs, ice bags, subcutaneous injec- Within one to three hours the spastic areas tions of hyaluronidase, or hyaluronidase showed progressive blanching. The spasm and procaine have been tried therapeu- was sufficient to limit the rate of flow of the tically without apparent success. A physio- infusion. If the catheter was injected for- logic antagonist of norepinephrine appeared cibly by syringe, however, the spastic seg- to be the logical choice as a prophylactic ment dilated and spasm did not recur. Al- agent. Since amino oxidase, which inactiv- though the spasm began to disappear spon- ates norepinephrine at the effector cell taneously after four to seven hours, extreme level,5, 13, 23 is not available, the adrenergic pallor of the vein persisted. On close in- blocling drugs phentolamine (Regitineg) spection vasa vasorum were originally vis- and tolazoline (Priscolineg) were em- ible in the adventitia of the infusion vein. ployed. As pallor of the infusion vein developed, these vasa vasorum presumably also be- Experimental Results came spastic since they could no longer be Four dogs were anesthetized with intra- seen. Only mild blanching of the tissues venous pentobarbital and the lower legs along the course of the vein was noted in shaved. Three ml. of a five per cent dex- three of the five animals. After six to eight trose solution containing 8 mg. of norepi- hours the infusion was discontinued and nephrine were injected subcutaneously with the vein excised for microscopic The study. a 26-gauge hypodermic needle in the cen- were wounds sutured, and the dogs given ter of the shaved areas, and the injections penicillin. No sloughs developed. repeated every 20 minutes for four to six Two dogs were handled in an identical hours. In the sixteen legs so treated, only manner except that they were first bled five developed sloughs. rapidly until the blood pressure fell to 50 The experiments were then repeated in mm. of mercury. Both of these dogs devel- a new series of 17 dogs in which rapid oped distinct blanching of the tissues ad- bleeding preceded the norepinephrine in- CLOSE, FRACKELTON AND KORY Annals of Surgery 46 January 1958 TABLE I. Experimental Incidence of Slough Following Repeated Subcutaneous Injections of Norepinephrine Average Minimum Dura- Number of Number of tion of Exposure to Legs Legs Per Cent Norepinephrine Injections Injected Sloughed Sloughed Normotensive dogs 5 hours 16 5 31 Hypotensive dogs 51 hours 32 28 88 jections. Each of these dogs received 1.5 four instances norepinephrine injections mg. of heparin per Kg. of body weight and were continued for two hours after Regi- then was bled rapidly until the mean ar- tine® was given. terial blood pressure fell to 50 mm. of Hg. The results of these trials are outlined in Norepinephrine injections were then given Table II. In none of the 16 legs treated in each dog's four legs at 20 minute in- with Regitineg, with or without hyaluron- tervals as in the first series without further idase, did a slough develop in contrast to bleeding or transfusion. Sixteen of the 17 the 16 control legs, all of which developed dogs survived. One front leg and one hind sloughs. In none of the 7 legs treated with leg of each dog were used as controls. A Priscoline®, with or without hyaluronidase, slough resulted in 28 of these 32 control did a slough develop despite the appear- legs (Table I). ance of slough in each control leg. Hy- The contralateral 32 extremities were aluronidase alone not only failed to prevent used for testing the efficacy of several drugs slough in all five legs, but these sloughs in the prevention of slough. After 4 to 6 were as large as or larger than those in the hours of exposure to norepinephrine, dur- control legs. ing which interval the injected areas be- III. Discussion came pale, cold and boggy, the ischemic areas were infiltrated with the following The course of events during prolonged prophylactic drug combinations: 1.5 mg. of continuous intravenous administration of Regitine® with 75 units of hyaluronidase- norepinephrine strongly suggests that dif- 8 legs; 1.0 mg. of Regitine® with 75 units of fusion of the drug through the severely hyaluronidase-4 legs; 1.0 mg. of Regitine® ischemic vein wall resulted in ischemia of without hyaluronidase-4 legs; 15 mg. of the adjacent tissues. Indirect evidence for Priscoline®-3 legs; 15 mg. of Priscoline® this concept is the fact that the ischemia with 75 units of hyaluronidase-4 legs; 75 paralleled the entire course of the infusion units of hyaluronidase alone-5 legs. Each vein above the tip of the catheter, and the drug or drug combination injected was di- fact that continuous backflow through trib- luted to 8 ml. with normal saline, the con- utary veins appeared to be prevented by tralateral control leg being infiltrated at the spasm. same time with 8 ml. of normal saline. Thus The important role of increased sensi- for each treated leg the contralateral leg tivity of the smaller vessels to chemical served as a control, and no treated legs stimuli in hemorrhagic hypotension is dem- were considered in the results unless the onstrated by the increase in the incidence control leg developed a slough.
Load more

Recommended publications
  • Index Vol. 12-15
    353 INDEX VOL. 12-15 Die Stichworte des Sachregisters sind in der jeweiligen Sprache der einzelnen Beitrage aufgefiihrt. Les termes repris dans la Table des matieres sont donnes selon la langue dans laquelle l'ouvrage est ecrit. The references of the Subject Index are given in the language of the respective contribution. 14 AAG (Alpha-acid glycoprotein) 120 14 Adenosine 108 12 Abortion 151 12 Adenosine-phosphate 311 13 Abscisin 12, 46, 66 13 Adenosine-5'-phosphosulfate 148 14 Absorbierbarkeit 317 13 Adenosine triphosphate 358 14 Absorption 309, 350 15 S-Adenosylmethionine 261 13 Absorption of drugs 139 13 Adipaenin (Spasmolytin) 318 14 - 15 12 Adrenal atrophy 96 14 Absorptionsgeschwindigkeit 300, 306 14 - 163, 164 14 Absorptionsquote 324 13 Adrenal gland 362 14 ACAI (Anticorticocatabolic activity in­ 12 Adrenalin(e) 319 dex) 145 14 - 209, 210 12 Acalo 197 15 - 161 13 Aceclidine (3-Acetoxyquinuclidine) 307, 13 {i-Adrenergic blockers 119 308, 310, 311, 330, 332 13 Adrenergic-blocking activity 56 13 Acedapsone 193,195,197 14 O(-Adrenergic blocking drugs 36, 37, 43 13 Aceperone (Acetabutone) 121 14 {i-Adrenergic blocking drugs 38 12 Acepromazin (Plegizil) 200 14 Adrenergic drugs 90 15 Acetanilid 156 12 Adrenocorticosteroids 14, 30 15 Acetazolamide 219 12 Adrenocorticotropic hormone (ACTH) 13 Acetoacetyl-coenzyme A 258 16,30,155 12 Acetohexamide 16 14 - 149,153,163,165,167,171 15 1-Acetoxy-8-aminooctahydroindolizin 15 Adrenocorticotropin (ACTH) 216 (Slaframin) 168 14 Adrenosterone 153 13 4-Acetoxy-1-azabicyclo(3, 2, 2)-nonane 12 Adreson 252
    [Show full text]
  • Adrenoceptors Regulating Cholinergic Activity in the Guinea-Pig Ileum 1978) G.M
    - + ! ,' Br. J. Pharmac. (1978), 64, 293-300. F'(O t.,," e reab- ,ellular PHARMACOLOGICAL CHARACTERIZATION OF THE PRESYNAPTIC _-ADRENOCEPTORS REGULATING CHOLINERGIC ACTIVITY IN THE GUINEA-PIG ILEUM 1978) G.M. Departmentof Pharmacology,Allen and HzmburysResearchLimited, Ware, Hertfordshire,SG12 ODJ I The presynaptic ct-adrenoceptors located on the terminals of the cholinergic nerves of the guinea- pig myenteric plexus have been characterized according to their sensitivities to at-adrenoceptor agonists and antagonists. 2 Electrical stimulation of the cholinergic nerves supplying the longitudinal muscle of the guinea-pig ! ileum caused a twitch response. Clonidine caused a concentration-dependent inhibition of the twitch i response; the maximum inhibition obtained was 80 to 95_o of the twitch response. Oxymetazoline and xylazine were qualitatively similar to clonidine but were about 5 times less potent. Phenylephrine and methoxamine also inhibited the twitch response but were at least 10,000 times less potent than clonidine. 3 The twitch-inhibitory effects of clonidine, oxymetazoline and xylazine, but not those of phenyl- ephrine or methoxamine, were reversed by piperoxan (0.3 to 1.0 lag/ml). 4 Lysergic acid diethylamide (LSD) inhibited the twitch response, but also increased the basal tone of the ileum. Mepyramine prevented the increase in tone but did not affect the inhibitory action of LSD. Piperoxan or phentolamine only partially antagonized the inhibitory effect of LSD. 5 Phentolamine, yohimbine, piperoxan and tolazoline were potent, competitive antagonists of the inhibitory effect of clonidine with pA2 values of 8.51, 7.78, 7.64 and 6.57 respectively. 6 Thymoxamine was a weak antagonist of clonidine; it also antagonized the twitch-inhibitory effect of morphine.
    [Show full text]
  • Drug Code List Version 11.2 Revised 9/11/17 List Will Be Updated Routinely
    Drug Code List Version 11.2 Revised 9/11/17 List will be updated routinely Disclaimer: For drug codes that require an NDC, coverage depends on the drug NDC status (rebate eligible, Non-DESI, non-termed, etc) on the date of service. Note: Physician/Facility-administered medications are reimbursed using the Centers for Medicare and Medicaid Services (CMS) Part B Drug pricing file found on the CMS website--www.cms.hhs.gov. In the absence of a fee, pricing may reflect the methodolgy used for retail pharmacies. Highlights represent updated material for each specific revision of the Drug Code List. Code Description Brand Name NDC NDC unit Category Service AC CAH P NP MW MH HS PO OPH HI IDT DC Special Instructions Requir of Limits OP OP F ed measure 90281 human ig, im Gamastan Yes ML Antisera NONE X X X X Closed 3/31/13. 90283 human ig, iv Gamimune, Yes ML Antisera NONE X X X X Closed 3/31/13. Cost invoice required with claim. Restricted to ICD-9 diagnoses codes 204.10 - 204.12, Flebogamma, 279.02, 279.04, 279.06, 279.12, 287.31, and 446.1, and must be included on claim form, effective 10/1/09. Gammagard 90287 botulinum antitoxin N/A Antisera Not Covered 90288 botulism ig, iv No ML NONE X X X X Requires documentation and medical review 90291 cmv ig, iv Cytogam Yes ML Antisera NONE X X X X Closed 3/31/13. 90296 diphtheria antitoxin No ML NONE X X X X 90371 hep b ig, im Bayhep B, Yes ML Antisera NONE X X X X Closed 3/31/13.
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]
  • With [3H]Mepyramine (Trieyclic Antidepressants/Antihistamine/Neurotransmitter/Amitriptyline) VINH TAN TRAN, RAYMOND S
    Proc. Nati. Acad. Sci. USA Vol. 75, No. 12, pp. 6290-6294,, December 1978 Neurobiology Histamine H1 receptors identified in mammalian brain membranes with [3H]mepyramine (trieyclic antidepressants/antihistamine/neurotransmitter/amitriptyline) VINH TAN TRAN, RAYMOND S. L. CHANG, AND SOLOMON H. SNYDER* Departments of Pharmacology and Experimental Therapeutics, and Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205 Communicated by Julius Axelrod, August 30,1978 ABSTRACT The antihistamine [3H mepyramine binds to Male Sprague-Dawley rats (150-200 g) were killed by cer- HI histamine receptors in mammalian brain membranes. vical dislocation, their brains were rapidly removed and ho- Potencies of H1 antihistamines at the binding sites correlate mogenized with a Polytron for 30 min (setting 5) in 30 vol of with their pharmacological antihistamine effects in the guinea pig ileum. Specific [3Himepyramine binding is saturable with ice-cold Na/K phosphate buffer (50 mM, pH 7.5), and the a dissociation constant of about 4 nM in both equilibrium and suspension was centrifuged (50,000 X g for 10 min). The pellet kinetic experiments and a density of 10pmolper gram ofwhole was resuspended in the same volume of fresh buffer and cen- brain. Some tricyclic antidepressants are potent inhibitors of trifuged, and the final pellet was resuspended in the original secific [3Hmepamine binding. Regional variations of volume of ice-cold buffer by Polytron homogenization. Calf [3Hjmepyramine ing do not correlate with variations in brains were obtained from a local abattoir within 2 hr after the endogeneous histamine and histidine decarboxylase activity. death of the animals and transferred to the laboratory in ice- Histamine is a neurotransmitter candidate in mammalian brain cold saline.
    [Show full text]
  • Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1
    vr_meds_ex01_3b_0825s Coding Manual Supplement MEDNAME OTHER_CODE ATC_CODE SYSTEM THER_GP PHRM_GP CHEM_GP SODIUM FLUORIDE A12CD01 A01AA01 A A01 A01A A01AA SODIUM MONOFLUOROPHOSPHATE A12CD02 A01AA02 A A01 A01A A01AA HYDROGEN PEROXIDE D08AX01 A01AB02 A A01 A01A A01AB HYDROGEN PEROXIDE S02AA06 A01AB02 A A01 A01A A01AB CHLORHEXIDINE B05CA02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D08AC02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D09AA12 A01AB03 A A01 A01A A01AB CHLORHEXIDINE R02AA05 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S01AX09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S02AA09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S03AA04 A01AB03 A A01 A01A A01AB AMPHOTERICIN B A07AA07 A01AB04 A A01 A01A A01AB AMPHOTERICIN B G01AA03 A01AB04 A A01 A01A A01AB AMPHOTERICIN B J02AA01 A01AB04 A A01 A01A A01AB POLYNOXYLIN D01AE05 A01AB05 A A01 A01A A01AB OXYQUINOLINE D08AH03 A01AB07 A A01 A01A A01AB OXYQUINOLINE G01AC30 A01AB07 A A01 A01A A01AB OXYQUINOLINE R02AA14 A01AB07 A A01 A01A A01AB NEOMYCIN A07AA01 A01AB08 A A01 A01A A01AB NEOMYCIN B05CA09 A01AB08 A A01 A01A A01AB NEOMYCIN D06AX04 A01AB08 A A01 A01A A01AB NEOMYCIN J01GB05 A01AB08 A A01 A01A A01AB NEOMYCIN R02AB01 A01AB08 A A01 A01A A01AB NEOMYCIN S01AA03 A01AB08 A A01 A01A A01AB NEOMYCIN S02AA07 A01AB08 A A01 A01A A01AB NEOMYCIN S03AA01 A01AB08 A A01 A01A A01AB MICONAZOLE A07AC01 A01AB09 A A01 A01A A01AB MICONAZOLE D01AC02 A01AB09 A A01 A01A A01AB MICONAZOLE G01AF04 A01AB09 A A01 A01A A01AB MICONAZOLE J02AB01 A01AB09 A A01 A01A A01AB MICONAZOLE S02AA13 A01AB09 A A01 A01A A01AB NATAMYCIN A07AA03 A01AB10 A A01
    [Show full text]
  • Selection of Vasodilator Therapy for Severe Raynaud's Phenomenon by Sequential Arterial Infusion
    Ann Rheum Dis: first published as 10.1136/ard.44.3.151 on 1 March 1985. Downloaded from Annals of the Rheumatic Diseases, 1985; 44, 151-154 Selection of vasodilator therapy for severe Raynaud's phenomenon by sequential arterial infusion I JON RUSSELL AND RICHARD A WALSH From the Department of Medicine, Divisions of Clinical Immunology and Cardiology, the University of Texas Health Science Center at San Antonio, USA. SUMMARY Two young adults with impending gangrene due to persistent Raynaud's vasospasm were studied by sequential intra-arterial (IA) infusion of three vasodilatory drugs while arterial pressure and plethysmographic digital pulse volume were continuously monitored. The results of the IA infusion accurately predicted relief from vasospastic symptoms by oral drugs of the same class. This method may be useful in selecting the most effective vasodilator for patients with severe vasospasm. Key words: vasodilatation, tolazoline, hydralazine, diltiazem, phenoxybenzamine. Raynaud's phenomenon may occur as an isolated (PVR-4, Life Sciences Incorporated, Greenwich, copyright. problem or as one manifestation of a major clinical CT). This semisegmental plethysmograph uses an syndrome. The management of infrequent vasospas- air-containing cuff round the proximal or distal tic episodes can be as simple as avoidance of cold, phalanx to plot pulsations as wave fortns on a strip wearing of gloves, or windmilling the affected arm recorder.5 By inflating a second cuff round the to override the increased vascular tone.' For pa- proximal phalanx the pressure required to obliterate tients with very frequent or persistent attacks a pulsation at the distal phalanx was determined, and variety of chemotherapeutic remedies have been it was defined as the finger systolic pressure.
    [Show full text]
  • Redalyc.Effcts of Cassia Podocarpa Leaves Extracts on the Rat Ileum And
    Boletín Latinoamericano y del Caribe de Plantas Medicinales y Aromáticas ISSN: 0717-7917 [email protected] Universidad de Santiago de Chile Chile Akomolafe, R.O.; Adeoshun, I.O.; Elujoba, A. A.; Iwalewa, E.O.; Ayoka, A.O. Effcts of cassia podocarpa leaves extracts on the rat ileum and colon (in vitro) Boletín Latinoamericano y del Caribe de Plantas Medicinales y Aromáticas, vol. 3, núm. 3, mayo, 2004, pp. 52-57 Universidad de Santiago de Chile Santiago, Chile Available in: http://www.redalyc.org/articulo.oa?id=85630303 How to cite Complete issue Scientific Information System More information about this article Network of Scientific Journals from Latin America, the Caribbean, Spain and Portugal Journal's homepage in redalyc.org Non-profit academic project, developed under the open access initiative BLACPMA Vol. 3 Nº 3 Mayo 2004 52 ARTICULOS stimulated by the extract. With this results therefore, C. podocarpa leaves could be EFFCTS OF CASSIA PODOCARPA substituted for C. acutifolia leaves as LEAVES EXTRACTS ON THE RAT vegetable laxative. ILEUM AND COLON (IN VITRO) KEY WORDS: Motility, Anthraquinone, Allosteric activation. 2* 1 R.O. AKOMOLAFE , I.O. ADEOSHUN , 3 4 A.A. ELUJOBA , E.O. IWALEWA RESUMEN: La etnofarmacología y los AND informes científicos indican el uso hojas de C. 1 A.O. AYOKA podocarpa como purgante. Este estudio intenta encontrar el efecto in vitro de su Recibido: 16 May 2003 infusión ácuosa (ACPL) y los methanolic Recibido corregido: 1 September 2003 (MCPL) en el intestines de ratas, usando Aceptado: 30 November 2003 hojas de C. acutifolia (ACAL y MCAL) como la norma de la referencia.
    [Show full text]
  • Xylazine Tolazoline
    United States Department of Agriculture Agricultural Marketing Service | National Organic Program Document Cover Sheet https://www.ams.usda.gov/rules-regulations/organic/national-list/petitioned Document Type: ☐ National List Petition or Petition Update A petition is a request to amend the USDA National Organic Program’s National List of Allowed and Prohibited Substances (National List). Any person may submit a petition to have a substance evaluated by the National Organic Standards Board (7 CFR 205.607(a)). Guidelines for submitting a petition are available in the NOP Handbook as NOP 3011, National List Petition Guidelines. Petitions are posted for the public on the NOP website for Petitioned Substances. ☒ Technical Report A technical report is developed in response to a petition to amend the National List. Reports are also developed to assist in the review of substances that are already on the National List. Technical reports are completed by third-party contractors and are available to the public on the NOP website for Petitioned Substances. Contractor names and dates completed are available in the report. Xylazine/Tolazoline Livestock 1 2 Identification of Petitioned Substance 3 4 Chemical Names: 43 5 Xylazine 44 Trade Names: 6 Xylazine 45 Xylazine 7 Xylazine Hydrochloride 46 AnaSed® LA 8 Xylazine Monohydrochloride 47 Rompun® 9 N-(2,6-Diphenylmethyl)-5,6-dihydro-4H-1,3- 48 TranquiVed Injection 10 thiazin-2-amine 49 X-Ject SA 11 N-(2,6-Diphenylmethyl)-5,6-dihydro-4H-1,3- 50 XylaMed™Celactal 12 thiazin-2-amine hydrochloride 51 13 52
    [Show full text]
  • Drugs, Poisons and Controlled Substances Act 1981
    1834 ANNO TRICESIMO ELIZABETHAE SECUNDAE REGINAE VICTORIA Drugs, Poisons and Controlled Substances Act 1981 No. 9719 An Act to re-enact with Amendments the Law relating to Drugs, Poisons and Controlled Substances, to amend the Health Act 1958 and the Crimes Act 1958 and for other purposes. [Assented to 12 January 1982] BE IT ENACTED by the Queen's Most Excellent Majesty by and with the advice and consent of the Legislative Council and the Legislative Assembly of Victoria in this present ParUament assembled and by the authority of the same as follows (that is to say): Short tiUe. 1. (1) This Act may be cited as the Drugs, Poisons and Controlled Substances y4cM981. Commenco- (2) The several provisions of this Act shall come into operation ment. on a day or on the respective days to be fixed by proclamation or successive proclamations of the Governor in Council published in the Government Gazette. Arrangement (3) This Act is divided into Parts and Divisions as follows: of Act. Part I.—Introductory and Transitional ss. 2-11. Part II.—Poisons and Controlled Substances ss. 12-55. Division 1—Classification s. 12. Division 2—Authorized Persons ss. 13-14. Division 1981 Drugs, Poisons and Controlled Substances No. 9719 2335 Division 3—Poisons Advisory Committee ss. 15-18. Division 4—Licensed Persons s. 19. Division 5—Special Poisons s. 20. Division 6—Industrial, Educational and Laboratory Permits s. 21. Division 7—Issue of Licences and Permits s. 22. Division 8—Manufacture and Sale of Poisons or . Controlled Substances ss. 23-30. Division 9—Trade or Proprietary Poisons s.
    [Show full text]
  • Mitigating the Inhibition of Human Bile Salt Export Pump by Drugs
    DMD Fast Forward. Published on September 7, 2012 as DOI: 10.1124/dmd.112.047068 DMD FastThis Forward. article has not Published been copyedited on andSeptember formatted. The 7, final 2012 version as doi:10.1124/dmd.112.047068may differ from this version. DMD #47968 Mitigating the inhibition of human Bile Salt Export Pump by drugs: opportunities provided by physicochemical property modulation, in-silico modeling and structural modification Daniel J. Warner, Hongming Chen, Louis-David Cantin, J. Gerry Kenna, Simone Stahl, Clare L. Walker, Tobias Noeske. Department of Medicinal Chemistry, AstraZeneca R&D Montreal, Montreal, Quebec, H4S Downloaded from 1Z9, Canada (DJW, LDC) Computational Sciences, Discovery Sciences, AstraZeneca R&D Mölndal, Pepparedsleden dmd.aspetjournals.org 1, Mölndal 43183, Sweden (HC) Molecular Toxicology, Global Safety Assessment, AstraZeneca, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK (JGK, SS, CLW) Global Safety Assessment, AstraZeneca R&D Mölndal, Pepparedsleden 1, Mölndal 43183, at ASPET Journals on October 10, 2021 Sweden (TN) 1 Copyright 2012 by the American Society for Pharmacology and Experimental Therapeutics. DMD Fast Forward. Published on September 7, 2012 as DOI: 10.1124/dmd.112.047068 This article has not been copyedited and formatted. The final version may differ from this version. DMD #47968 Inhibition of the human Bile Salt Export Pump by drugs. Corresponding author: Tobias Noeske Global Safety Assessment AstraZeneca R&D Mölndal S-431 83 Mölndal, Sweden Phone: +46-31-7064002 Mobile: +46-727-158344
    [Show full text]
  • PRESYNAPTIC O-ADRENOCEPTORS REGULATING CHOLINERGIC ACTIVITY in the GUINEA-PIG ILEUM
    Br. J. Pharmac. (1978), 64, 293-300. PHARMACOLOGICAL CHARACTERIZATION OF THE PRESYNAPTIC o-ADRENOCEPTORS REGULATING CHOLINERGIC ACTIVITY IN THE GUINEA-PIG ILEUM G.M. DREW Department of Pharmacology, Allen and Hanburys Research Limited, Ware, Hertfordshire, SG12 ODJ 1 The presynaptic ax-adrenoceptors located on the terminals of the cholinergic nerves of the guinea- pig myenteric plexus have been characterized according to their sensitivities to a-adrenoceptor agonists and antagonists. 2 Electrical stimulation of the cholinergic nerves supplying the longitudinal muscle of the guinea-pig ileum caused a twitch response. Clonidine caused a concentration-dependent inhibition of the twitch response; the maximum inhibition obtained was 80 to 95% of the twitch response. Oxymetazoline and xylazine were qualitatively similar to clonidine but were about 5 times less potent. Phenylephrine and methoxamine also inhibited the twitch response but were at least 10,000 times less potent than clonidine. 3 The twitch-inhibitory effects of clonidine, oxymetazoline and xylazine, but not those of phenyl- ephrine or methoxamine, were reversed by piperoxan (0.3 to 1.0 jg/ml). 4 Lysergic acid diethylamide (LSD) inhibited the twitch response, but also increased the basal tone of the ileum. Mepyramine prevented the increase in tone but did not affect the inhibitory action of LSD. Piperoxan or phentolamine only partially antagonized the inhibitory effect of LSD. 5 Phentolamine, yohimbine, piperoxan and tolazoline were potent, competitive antagonists of the inhibitory effect of clonidine with pA2 values of 8.51, 7.78, 7.64 and 6.57 respectively. 6 Thymoxamine was a weak antagonist of clonidine; it also antagonized the twitch-inhibitory effect of morphine.
    [Show full text]